Dapagliflozin FDA Rejection Not End of SGLT2 Inhibitors
The FDA's decision to reject AstraZeneca plc and Bristol-Myers Squibb Co.'s Type II diabetes drug dapagliflozin last week was no surprise, given the drug's spotty safety record and a negative advisory panel vote. But the rejection isn't necessarily a death sentence for dapagliflozin, or for other SGLT2 inhibitors in development.
Sign up for Perspectives FREE e-mail newsletter.
Outside the U.S.: 1-404-262-5423
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST